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Essentials
• Initial immune cell interactions leading to factor (F) VIII immunity are not well characterized.
• We assessed cellular interactions and expression profiles in hemophilia A mice.
• MARCO+, followed by SIGLEC1+ and SIGNR1+ macrophages co-localize most with human FVIII.
• The splenic transcriptome highlights potential therapeutic targets to prevent inhibitors.
Summary. Background: Developing factor VIII (FVIII)
inhibitory antibodies is the most serious complication in hemophilia A treatment, representing a significant health and economic burden. A better understanding of the early events in an immune response leading to this outcome may provide insight into inhibitor development. Objective: To identify early mediators of FVIII immunity and to detail immune expression profiles in the spleen and liver. Methods: C57Bl/6 F8 E16 knockout mice were infused with 5-20 lg (2000-8000 IU kg À1 ) of recombinant FVIII. Spleens were frozen at various time-points post-infusion and stained for FVIII and cellular markers. Splenic and liver RNA expression analysis was performed 3 h post-infusion of 0.6 lg (240 IU kg
À1
) FVIII by nCounter technology using a 561-gene immunology panel. Results: FVIII localization in the spleen did not change over 2.5 h. We observed significantly higher colocalization of FVIII with MARCO + cells compared with SIGLEC1 + and SIGNR1 + in the splenic marginal zone. FVIII exhibited little co-localization with CD11c + dendritic cells and the macrophage mannose receptor, CD206. Following FVIII infusion, the splenic mRNA profiling identified genes such as Tnfaip6 and Il23r, which are implicated in chemotaxis and a proinflammatory Th17 response, respectively. In contrast, an upregulation of Gfi1 in the liver suggests an anti-inflammatory environment. Conclusions: FVIII co-localizes predominantly with marginal zone macrophages (MARCO
Introduction
The development of anti-factor VIII (FVIII) antibodies, or inhibitors, remains the most significant complication in the treatment of up to 30% of severe hemophilia A (HA) patients [1] . Our current knowledge of the early events in this response is limited and inconsistent. Understanding these initiating events will help better target therapeutic action to inhibit this response, thus limiting the health and economic burden of immune tolerance induction (ITI).
The observation of decreasing inhibitory titers in parallel with decreasing CD4 + T cell numbers in HIV-infected HA patients has established that a classical T-cell-dependent immune response is necessary for the development of FVIII inhibitory antibodies [2] . However, the type of antigen presenting cell (APC) responsible for the initial activation of FVIII-specific T cells has not been identified. In mouse models, intravenously-infused FVIII has been described to be largely sequestered in the mouse liver as well as the marginal zone of the mouse spleen [3] . The cell types with which FVIII interacts in the spleen are not well described in the literature, where reports are conflicting, localizing FVIII with F4/80 red pulp macrophages, with the marginal zone metallophilic macrophage (MZMM) marker Sialic acid-binding Ig-like Lectin-1 (SIGLEC1; also known as CD169 or sialoadhesin), or just concentrically at the exterior of the marginal zone [3] [4] [5] . Moreover, no receptor has been shown to have an in vivo role in eliciting FVIII immunity. Again, conflicting evidence has suggested that the exposed mannose residues on FVIII at Asn 239 and Asn 2118 are implicated in FVIII uptake via the macrophage mannose receptor (CD206) on dendritic cells (DCs) and macrophages, leading to the proliferation of FVIII-specific CD4 + T cells [6, 7] . Here, we assess in greater detail the initial interface between FVIII and the immune system in HA mice, and profile the microenvironments of the liver and spleen that may provide insights into how each organ responds to FVIII. These data may narrow the search for receptors involved in FVIII uptake and antigen presentation, and ultimately have implications for early therapeutic interventions targeting specific cellular subsets, as well as signaling pathways that subsequently lead to a FVIII immune response.
Materials and methods

Mice and FVIII treatment
Male and female HA C57Bl/6 mice aged 8-12 weeks were used in all experiments. These mice possess an interruption of exon 16 of the F8 gene, resulting in a severe HA phenotype and consistently develop FVIII inhibitors when exposed to human FVIII via intravenous infusions [8, 9] . Recombinant human FVIII (Advate; Shire, Dublin, Ireland) suspended in saline was used in these studies. Na€ ıve HA mice were infused with 5-20 lg FVIII via the tail vein in a 250-lL volume. All mouse experiments were approved by the Queen's University Animal Care Committee.
FVIII binding and flow cytometry
Mice were anesthetized with 5% isofluorane and sacrificed by cervical dislocation. Spleens were removed and digested in Spleen Dissociation Medium (STEMCELL Technologies, Vancouver, BC, Canada). Single-cell splenocyte suspensions were then incubated with increasing concentrations of human FVIII for 30 min at 4°C in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 lM penicillin/streptomycin and 50 lM 2-mercaptoethanol. After FVIII treatment, cells were washed and incubated with an Fc blocker (CD16/ 32; eBioscience, San Diego, CA, USA) for 15 min at 4°C, followed by a 30-min antibody incubation at 4°C to detect binding of FVIII using a FITC-conjugated polyclonal sheep anti-human FVIII antibody (Affinity Biologicals, Ancaster, Canada), as well as cell expression markers B220/CD45R-PE-Cy7 (clone: RA3-6B2; eBioscience), CD11c-APC (clone: N418; STEMCELL Technologies), CD11b-PE (clone: M1/70; eBioscience), F4/80-PE (clone: BM8; eBioscience) and CD206-APC (clone: MR5D3; BD Biosciences, Franklin Lakes, NJ, USA). Cells were fixed in 1% paraformaldehyde and data were acquired on a Miltenyi MACSQuant Analyzer, and analyzed in FlowJo 10.
Immunofluorescent and immunohistochemical staining
Mice were sacrificed as described above. Organs were harvested at various time-points between 30 min and 3 h post-FVIII injection. Tissues were embedded in Tissue-Tek O.C.T. Compound (Sakura, Torrance, CA, USA) and frozen in the vapour phase of liquid nitrogen and subsequently processed into 7-lm sections. Tissue sections were then fixed in ice-cold acetone for 10 min and blocked using 10% normal mouse serum and 2% fetal bovine serum in phosphate buffered saline (PBS) for 30 min. FVIII was detected using the human anti-human monoclonal antibodies VK34, KM33 and EL14 [10] [11] [12] . Factor IX and CD31 were detected using a polyclonal sheep anti-human FIX antibody (Affinity Biologicals) and a rat anti-mouse CD31 antibody (clone: SZ31; Dianova, Hamburg, Germany). Mouse von Willebrand factor (mVWF) was detected using a polyclonal rabbit anti-human VWF antibody (DAKO, Glostrup, Denmark). Cellular subsets were detected using monoclonal antibodies against CD169/ SIGLEC1 (clone: SER4), MARCO (clone: ED31), SIGNR1 (clone: 22D1), CD11c (clone: N418; eBioscience), CD206 (clone: MR5D3; BD Biosciences), CD11b (clone: M1/70; eBioscience) and F4/80 (clone: BM8; eBioscience) [13] [14] [15] . The following isotype controls were used where appropriate: pooled human IgG, sheep IgG, rat IgG2aj, rat IgG2bj, hamster IgG (eBioscience) and rabbit IgG (DAKO).
For B220 staining (clone: RA3-6B2; eBioscience), in order to facilitate detection, 25 lg of FVIII was intravenously infused into na€ ıve HA mice, and spleens were fixed in formalin 30 min after infusion and embedded in paraffin 24 h later. Tissue sections (7 lm) were stained for B220 and FVIII using a polyclonal anti-FVIII antibody (Affinity Biologicals).
Slides were imaged using a Leica TCS SP8 confocal microscope or a Nikon Eclipse Ni-E microscope using a 409 objective and analyzed using Fiji Coloc2 plugin (https://imagej.net/Coloc_2). Co-localization was quantified using Pearson's correlation coefficients from at least one representative field of view from at least three biological replicates [16] .
FVIII and VWF binding assay
Immulon 4-HBX 96-well plates (Thermo Scientific, Waltham, MA, USA) were coated overnight with a polyclonal sheep anti-human FVIII antibody (Affinity Biologicals). Recombinant FVIII was captured for 2 h, followed by incubation with recombinant mVWF in 40 mM Ca 2+ for 2 h at 37°C. Bound mVWF was detected using an HRPconjugated rabbit anti-human VWF antibody (Dako). FVIII was detected using either an HRP-conjugated sheep anti-human FVIII antibody (Affinity Biologicals) or a cocktail of VK34, EL14 and KM33 (2 lg mL À1 ), followed by a goat anti-human IgG-HRP (Southern Biotech, Birmingham, AL, USA). Plates were read at 490 nm. FVIII was quantified relative to a standard curve generated using the appropriate detection antibodies. VWF binding was reported as optical density readings after 15 min.
RNA isolation and RNA expression analysis
Mouse livers and spleens were harvested 3 h post-treatment and RNA was preserved using RNAlater (Invitrogen, Carlsbad, CA, USA). Then 30 mg of tissue was homogenized manually, and subsequently passed through QIAshredder columns (Qiagen, Hilden, Germany). Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). RNA quality control cut-offs for A260/280 and A260/230 were 1.9 and 1.8 respectively. Then 100 ng of RNA was used to assess the expression of 561 mouse genes using the nCounter Mouse Immunology Gene Expression CodeSet. Data normalization was performed using the nSolver Analysis Software 3.0. Background subtraction was carried out by subtracting the geometric mean of eight negative controls from the dataset. Datasets were normalized using the geometric mean of 14 housekeeping genes and six positive controls. Values < 0 transcript counts were considered equal to 1. Statistical analysis was performed using Student's t-test with a significance threshold of P < 0.05. To maximize sensitivity, correction for multiple comparisons was not performed due to the subtle nature of the response to FVIII.
Statistical analysis
All data are presented as mean plus or minus the standard deviation (SD). Statistical comparisons between experimental conditions were evaluated using Student's t-test.
All P values are shown in the Figures. Heatmaps and dendrograms were generated using R and the gplots package.
Results
FVIII binds primarily to splenocytes expressing the surface marker B220/CD45R in vitro but not in vivo
To characterize major cell subsets capable of interacting with FVIII, we incubated splenocytes from FVIII-na€ ıve HA mice with increasing concentrations of FVIII at 4°C (Fig. 1A) . We then stained the splenocytes for FACS analysis. At saturating concentrations, up to 20% of splenocytes were able to bind to FVIII (Fig. 1B) . We further sorted the FVIII + cells using markers for pan-B cells (B220), pan-DCs (CD11c), monocytes (CD11b), red pulp macrophages (F4/80) and the mannose receptor (CD206). At both non-saturating and saturating concentrations of FVIII, the distribution of FVIII across these cell subsets did not change. The majority of FVIII (67.8% AE 3.5%, 69.6% AE 2.7%, respectively) was localized with B220 + cells and CD206 + cells (14% AE 2.0%, 6.53% AE 1.5%, respectively) (Fig. 1C) . ), and isolated the spleens 30 min after infusion. Interestingly, we found that a 4-fold increase in FVIII dosage did not influence the localization of FVIII in the marginal zone of the spleen ( Fig. 2A) . In comparison, immunostaining of human factor IX (FIX) and human VWF infused into FVIII knockout (KO) and VWF KO mice, respectively, showed FIX co-localizing with CD31 + endothelial-like cells and VWF in the marginal zone as well as the red pulp ( Figure S1 ). We next asked whether the localization of FVIII changes over time. FVIII was detected up to 2.5 h after infusion (Fig. 2B) . Regardless of the dose, we were unable to detect FVIII in the spleen after 3 h. All subsequent experiments use a 10-lg infusion of FVIII unless otherwise stated.
The high dose of FVIII used in this study may alter the pharmacodynamics interactions with murine VWF, resulting in an increase of VWF-free FVIII. We observed an accelerated rate of FVIII clearance as the dose increased from 240 IU kg À1 to 8000 IU kg À1 (Fig. 2C) . Surprisingly, we observed little co-localization of mouse VWF with human FVIII in the spleen, and this observation is not due to FVIII antigen masking by VWF ( Given our FACS data, we next asked if B220 + cells exhibit a similar degree of co-localization with FVIII in vivo. We did not observe FVIII staining in saline-injected controls (Fig. 3A) . In mice infused with FVIII, no co-localization of B220 and FVIII was observed (Fig. 3B) . Instead, FVIII was seen to localize outside the follicular regions.
Previous reports have implicated roles of DCs and the macrophage mannose receptor, CD206, in the uptake and presentation of FVIII in vitro using human monocyte-derived DCs [6] . Our FACS analyses on murine splenocytes also showed that CD206 + cells interact with FVIII in vitro; however, these studies on FVIII uptake have not been assessed in vivo. Here, we observed that CD206, and the monocyte/macrophage marker CD11b, were primarily found in the red pulp of the spleen, and exhibited little co-localization with intravenously infused FVIII (Fig. 3C) . Similarly, the pan-DC marker, CD11c, was found in both the red pulp as well as the marginal zone, but no direct overlap with FVIII was detected (Fig. 3D) . In summary, little correlation was observed between FVIII and CD11c (R = 0.22), CD206 (R = 0.15), CD11b (R = 0.18) and B220 (R = 0.34) (Fig. 3E ).
We next detected FVIII co-localization with marginal zone (MZ) macrophages using the markers MacrophageAssociated Receptor with COllagenous structure (MARCO; Fig. 4A ), marginal zone metallophilic macrophages (MZMM) using the marker SIGLEC1 (Fig. 4B) , and the Specific Intercellular adhesion molecule-3-Grabbing Nonintegrin-Related 1 C-type lectin (SIGNR1; Fig. 4C ). Pearson's R correlation was highest between FVIII and MARCO (R = 0.71), followed by SIGLEC1 (R = 0.58) and SIGNR1 (R = 0.50) (Fig. 4D ).
FVIII induces a proinflammatory transcriptional profile in the spleen and liver in vivo
To examine the effects of FVIII in the murine spleen upon infusion, we infused age-and littermate-matched male mice with either 0.6 lg (6 IU; 240 IU kg rFVIII or saline. This lower dose was used for clinical relevance, and is known to elicit 100% FVIII inhibitor development in this mouse model. Three hours after infusion, spleens were aseptically removed and total RNA was isolated. Transcriptional profiling, using nCounter technology, of a 561 immune response gene panel was used to compare FVIII-and vehicle-exposed mice (Fig. 5A) . Our results showed significant changes (P < 0.05) in 33 genes, and hierarchical clustering of the biological replicates suggests a distinct transcriptional profile in FVIII-treated mice (Fig. 5B) .
The liver is the other organ that plays a major role in mononuclear phagocyte system function, receiving a large blood volume and possessing several different populations of phagocytic cells. However, in contrast to the spleen, the liver is typically considered to provide a tolerogenic environment for bloodborne antigens. For these reasons, we performed a similar transcriptome analysis in livers exposed to FVIII for 3 h (Fig. 6A) . Our data show significant changes (P < 0.05) in 12 genes, and hierarchical clustering again suggests a distinct transcriptional profile in FVIII-treated mice (Fig. 6B) .
Discussion
A better understanding of the initial events leading to the development of FVIII inhibitors may provide avenues for therapeutic interventions to prevent what remains the greatest complication in treating HA.
Human monocyte-derived and murine bone marrowderived DCs and macrophages have remained the reference standard for investigating these responses. Our current knowledge suggests that these progenitor-derived DCs can internalize FVIII and present FVIII peptides in the context of MHC class II alleles, and that certain residues in the C1 and C2 domain contribute to FVIII uptake [17] [18] [19] [20] . Receptors that potentially mediate this uptake include SIGLEC5 [21] , the asialoglycoprotein receptor (ASGPR) [22] , CD206 [6] , CLEC4M [23] , LRP1 [24] and LDLR1 [25] . However, the in vivo relevance of these progenitor-derived antigen-presenting cell types and these receptors has not yet been established. Initial studies in mice implicated the liver and the spleen as the predominant reservoirs for FVIII clearance; however, there remains no consensus regarding the cellular interactions [3, 5] . Here, we have characterized in detail the early interactions of FVIII with innate immune cells in the spleen, and detailed the transcriptional profiles that are generated shortly after the interaction. We initially asked what cells in the spleen were capable of binding to FVIII without the confines of anatomical architecture and excluding the influence of blood-flowmediated biodistribution. In in vitro studies using splenocytes derived from FVIII-na€ ıve HA mice, we found that the majority of FVIII-binding cells also expressed the pan-B cell marker B220, and to a significantly lesser extent, CD11c, CD11b, F4/80 and CD206. It is possible that additional cell subsets contribute to FVIII binding and are not represented here due to inefficiencies in cell isolation and sorting potential (e.g. sinusoidal endothelium and macrophage subsets). The significant interaction of FVIII with B cells is unlikely to be mediated by the B-cell receptor given the scarcity of FVIII-specific B cells in FVIII-na€ ıve mice. This association is more likely via scavenger receptors, which implicates an innate immune response. Indeed, B cells also express an array of pattern recognition receptors, such as CD22, which can recognize sialic acid residues on FVIII and have been implicated in tolerance induction [26] . Furthermore, a small subset of B cells, marginal zone B cells, can facilitate complementmediated uptake and subsequent shuttling of antigens into the splenic follicle [27] . Specific depletion of MZ B cells has recently been described to reduce FVIII inhibitor development in mice; however, FVIII tolerance was not maintained upon repopulation [28] . Considering the dynamic and highly regulated interactions between MZ B cells and MZMs that regulate antigen shuttling, the mechanisms of FVIII transport through the spleen should be further investigated [29] . We next aimed to characterize the early cellular interactions with FVIII in vivo. It should be emphasized that these studies, in HA mice, take into account the interaction of infused FVIII with its carrier partner, mVWF. The use of supra-physiological doses of FVIII (2000-8000 IU kg
À1
) was found to exhibit accelerated clearance wherein high-dose FVIII is likely to exceed the carrying capacity of endogenous mouse VWF. The relevance of VWF-free FVIII, normally 2-5%, remains unclear [30, 31] . However, given recent evidence suggesting that VWF is immunoprotective for FVIII, it is possible that an increase of VWF-free FVIII is more immunogenic [32, 33] . Nevertheless, from an immunological perspective, the amount of FVIII used here is well within the typical range of immunogen doses. Indeed, higher doses of immunogens have been shown to select for a wider array of somatic B cell mutants, suggesting a more polyclonal response [34] .
Interestingly, we did not observe localization of FVIII with B220 + cells. This may be attributed either to mVWF-mediated inhibition or to the architecture of splenic circulation where the central arterioles empty into the red pulp and marginal zone sinus, thus bypassing the B220 + -rich follicular regions [35] . Surprisingly, costaining for FVIII and mVWF showed limited co-localization, with the latter observed in the marginal zone as well as the red pulp. Studies by Van Schooten et al. demonstrated that human VWF and FVIII localized to the same cells within the mouse spleen [4] . These contrasting findings may be attributed to the interspecies dynamics between mVWF and human FVIII, and potential differences in receptor localization between human and murine VWF. In addition, our experimental model does not differentiate between the clearance and synthesis of VWF.
We observed that FVIII localizes very specifically in the marginal zone of the spleen, and is detectable using our methods up to 3 h after infusion. Subsequent endocytosis of FVIII is likely to contribute to the loss of tertiary structure in the acidic endosome. Further characterization of FVIII localization found that, contrary to in vitro studies, FVIII does not interact, in its native state, with cells expressing the macrophage mannose receptor, CD206 or CD11c + DCs [6] . The lack of co-localization with CD206 + cells may be attributed to the masking of FVIII mannose glycans by endogenous mouse VWF [6] . Moreover, although DCs may not be the initial point of contact for FVIII, there are several non-canonical methods of antigen capture. For instance, DCs can acquire peptide-MHC class II complexes from other cells through a cell contact-dependent process known as trogocytosis, otherwise known as membrane transfer [36] . Other mechanisms include the intercellular transfer of MHC molecules via exosomes, or the sharing of cytoplasmic contents by tunneling nanotubules [37, 38] . These methods of transferring antigens have not been investigated for FVIII, but highlight new directions that may lead to a better understanding of FVIII immunobiology. In our studies we observed that FVIII localized with cells expressing the scavenger receptors MARCO and SIGNR1, representative of the marginal zone macrophages (MZM) [39, 40] , as well as SIGLEC1, a marker for MZMMs [13] . We observed a hierarchy of interaction wherein FVIII exhibited the most significant co-localization with MARCO + cells, followed by SIGLEC1, thus MZMs and MZMMs, respectively. Our findings provide support for both the findings of Navarrete et al. and those of Delignat et al. [3, 5] . Although we have not directly demonstrated binding of FVIII to these pattern recognition receptors, it is plausible that the glycan structures decorating FVIII can interact with these macrophage subsets via the sialic acid recognition domains on SIGNR1 and SIGLEC1 [41] [42] [43] .
The macrophage subsets identified here have been typically associated with rapid clearance of blood-borne bacteria and viruses, and are suggested to be dispensable for antigen presentation and induction of CD4 + and CD8 + T cells [44, 45] . However, there is evidence of antigen transfer from MZMMs to CD8 + DCs and the subsequent induction of cross-presentation to CD8 + cytotoxic T cells, as well as antigen-specific B-cell activation elicited directly by SIGLEC1 + macrophages [46, 47] . In contrast, SIGNR1 has been shown to contribute to the anti-inflammatory effect of intravenous immunoglobulin, whereas engagement of MARCO prevents antigen shuttling by marginal zone B cells and reduces the adaptive immune response [48, 49] . Moreover, SIGLEC1
+ MZMMs have been implicated in the maintenance of tolerance through the clearance of circulating apoptotic cells and recruitment of Foxp3 + T regulatory cells and DCs [50] . Collectively, these findings suggest that MZMs and MZMMs can induce both tolerance and immunity against FVIII, and that the balance is likely to be very tightly regulated.
We have previously profiled the transcriptome of DCs 24 h after in vivo exposure to FVIII; however, neither the large-scale splenocyte transcriptome nor earlier timepoints post-FVIII administration have been investigated [9] . We used nCounter technology to probe the two major organs implicated in clearance and immunogenicity, the liver and the spleen, respectively, 3 h after intravenous FVIII exposure. The genes identified here may highlight novel targets for the immunomodulation of the FVIII immune response. For instance, the gene Tnfaip6 was upregulated (5.47-fold) in response to FVIII in the spleen. The gene encodes for TNF alpha-induced protein 6, which is secreted in response to inflammatory stimuli such as IL-1, TNF and LPS, and it serves as a key anti-inflammatory mediator by sequestering chemokines of the CXC and CC families from the extracellular matrix [51, 52] . Although FVIII has previously been described to be void of inflammatory danger signals in an in vitro cellularbased model, it is possible that the in vivo delivery in mice stimulates an inflammatory signature and Tnfaip6 is upregulated as a homeostatic mechanism [53] . Moreover, the overall cytokine microenvironment plays a significant role in T-cell polarization. Indeed, the expression increase in IL23r (3.178-fold) augments the responsiveness of the IL23/IL23R signaling axis, which has been implicated in STAT3 induction, which subsequently stimulates the production of IL-6, IL-21 and IL-23, and is critical for IL-17 production, such that deletion results in a loss of IL-17-producing cells [54, 55] . These findings are consistent with the clinical observations of an early Th17 polarization in HA patients with inhibitors prior to the conversion to Th2 [56] . Given that HA mice regularly develop inhibitory antibodies against human FVIII, it is likely that this initial pro-inflammatory milieu is an essential prerequisite for the FVIII immune response, and further underlines a translationally relevant use of mice as a model for this disease.
Splenic genes that were downregulated in response to FVIII include Ctla4 (1.22-fold decrease), a T-cell inhibitory molecule whose engagement has been previously implicated in the prevention of FVIII inhibitors in mice [57] . Additionally, the decreased expression of the chemokine receptor Cxcr4 (2.18-fold decrease) may suggest the retention of lymphoid cells within the spleen. Indeed, small-molecular CXCR4 antagonists have been shown to reduce metastasis in several cancer models [58] .
The smaller number of genes with significantly altered expression patterns in the liver compared with the spleen is perhaps not surprising considering the size and relative numbers of immune cells in the liver. Gfi1, which was upregulated by 3.85-fold, acts to limit the inflammatory immune response, as shown in Gfi1-knockout mice, and is thus consistent with the hypothesis that the liver provides a tolerogenic environment for FVIII [59] . Interestingly, the natural killer (NK) cell receptor, Klrd1, was significantly downregulated in the liver. The KLRD1 receptor (also known as CD94) contains C-type lectin folds and forms a complex with inhibitory or activating members of the NKG2 intracellular signaling family and samples MHC class I peptides to regulate immune homeostasis [60] . The heterodimer of KLRD1 and activating NKG2D has been shown to bind to a2,3-sialylated biand tri-antennary N-glycans, the former of which is the most abundant glycan on FVIII [61, 62] . Thus, although NK cells have not been previously implicated in FVIII immunogenicity, the downregulation of Klrd1 may influence the activation status of NK cells, subsequently leading to a pro-or anti-inflammatory microenvironment.
Collectively, these data provide a comprehensive overview of the FVIII immune response within the first 3 h of intravenous administration. The anatomical architecture of the spleen appears to preclude the interaction of FVIII with B220+ B cells as observed in vitro, and instead directs FVIII to macrophages in the marginal zone, specifically MARCO + macrophages. After 3 h, FVIII in its native form is undetectable in the spleen, and we observed a transcriptional profile that suggests the modulation of co-stimulatory molecules and chemokines, as well as early Th17 polarization through STAT3. It is possible that upon initial internalization by MZMs and MZMMs, FVIII peptides, potentially bound to MHC class II, are transferred to DCs via exosomes or trogocytosis. Subsequent presentation to cognate CD4 + T cells activates downstream signaling, leading to anti-FVIII Th17 responses. Collectively, these data provide insight into novel therapeutic interventions, either at the initial point of FVIII contact with MARCO + macrophages or manipulating the T-cell polarization profile to downregulate Th17 responses. 
Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1 . Detection of human factor (F) IX and von Willebrand factor (VWF) in the spleen of F8 KO and VWF knockout (KO) mice. F8 KO mice were infused intravenously with either saline (A) or 5 lg of recombinant human FIX (B). Tissues were fixed in formalin 30 min after injection and embedded in paraffin. Tissue sections were stained for FIX, CD31 and F4/80 red pulp macrophages by immunofluorescence. VWF KO mice were infused intravenously with either saline (C) or 5 lg of highly purified plasma-derived von Willebrand factor (D), and stained for human VWF by IHC-DAB. Images were captured using a Nikon Eclipse Ni-E microscope using a 209 or 409 objective; scale bars indicate 100 lm. Images are representative of three biological replicates. Fig. S2 . Recombinant mouse von Willebrand factor (VWF) does not inhibit the detection of human factor (F) VIII. Recombinant FVIII was captured using a sheep anti-human FVIII polyclonal antibody (Affinity Biologicals). Recombinant mouse VWF was incubated in 40 mM Ca 2+ for 2 hours and detected using a cross-reacting rabbit anti-human VWF antibody (Dako). FVIII was detected using either an HRP-conjugated sheep antihuman FVIII polyclonal antibody (Affinity Biologicals) or a cocktail of EL14, KM33 and VK34, followed by corresponding goat anti-human IgG-HRP. Optical density was read at 490 nm.
